Sign up for ICER's Weekly View Newsletter

 

Weekly View


September 3, 2026

From the desk of Priya Ranade

Good morning, everyone.

We're in your inbox a day early so you'll catch us before Labor Day weekend. We hope everyone has a relaxing holiday. Now, let's see what happened this week...


ICER and the West Health Policy Center announced a new collaboration to develop the 2026 “Launch Price and Access Report”, an independent analysis of drug prices and patient access for newly launched FDA-approved treatments. ICER published its first report in 2025.

 

  • ICER’s President and CEO, Sarah K. Emond stated: "ICER is proud to work with a partner who shares our mission of addressing access and affordability challenges for patients. Together, we will provide an independent analysis on launch price trends over the past four years and assess patient access to newly launched medicines.”

 

  • West Health Policy Center's President and Chair, Timothy Lash, stated: "Prescription drugs are a key tool to enable healthy aging, but high prescription drug prices continue to put needed treatments out of reach for far too many Americans, including older adults. New drugs should improve people’s health, and the financial reward for developing them should reflect those improvements. Understanding the value of new drugs is critical for developing policies that ensure affordable access while also sending the signal to innovators that the best drugs get the best prices.”
 

ICER in the News

 

A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs

The New York Times

The New York Times covered the recent approval of Rasonque for pancreatic cancer and mentioned ICER’s Launch Price and Access Report from last year:

 

“Revolution Medicines set a sticker price of about $480,000 a year, or $663 a tablet, for its new pancreatic cancer drug — a cost that would have once been unthinkably high. Today, such prices are routine for cancer drugs… In 2024 alone, nine cancer drugs were approved and then introduced with sticker prices above $400,000 annually, according to a tally by the Institute for Clinical and Economic Review, which evaluates the value of medicines.

 

That these prices have become commonplace would have been hard to imagine two decades ago, when even the prospect of a $100,000-a-year cancer drug evoked fierce criticism.”

 
 
Pharmaceutical News

MUST READS


White House strikes new drug-pricing deals

Politico

President Donald Trump on Monday announced nine more deals with pharmaceutical companies to lower certain drug prices, the latest addition to his administration’s effort to address health care affordability. The most-favored-nation deals generally aim to compel companies to launch new medicines in the United States at prices similar to those charged in other wealthy nations and offer lower prices for many current drugs to state Medicaid programs, which provide health coverage for millions of low-income Americans.


The nine new drugmakers are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB. To date, 26 pharmaceutical companies have now announced deals with the Trump administration to lower their prices and bring more drug manufacturing to the U.S. In exchange, many of the companies are exempt from potential future tariffs.

Medicare’s GLP-1 Bridge Program Off To Fast Start, But How Will CMS Manage Demand?

Pink Sheet

The Medicare GLP-1 Bridge demonstration of short-term coverage for obesity drugs has enrolled 600,000 seniors in its first two months, CMS said. 


Based on an estimated 3.8 million Part D beneficiaries that qualify for Bridge, the program already has signed up 15% of eligible participants, at a monthly cost to Medicare of roughly $117M. The rapid uptake increases the pressure on CMS' plans for the program when the demonstration ends in late 2027.

UnitedHealthcare to nix prior auth on 1,700 services on Oct. 1

Fierce Healthcare

UnitedHealthcare said earlier this year that it was aiming to eliminate 30% of prior authorization requirements by the end of 2026. Now, the insurer is offering a deeper look at codes that will no longer be subject to prior auth as of Oct. 1, including adjustments across its commercial, Medicaid, Medicare Advantage and individual market coverage. About 1,700 codes are included overall.

Florida attorney general sues PBMs Express Scripts, Prime over alleged price fixing

Healthcare Dive

Florida’s attorney general is suing Express Scripts and Prime Therapeutics, arguing that a deal between the rival pharmacy benefit managers allowed Prime to adopt Express Scripts’ lower pharmacy reimbursement rates and violated antitrust laws.


The suit, filed last week in Florida’s circuit court, alleges that Prime and Cigna-owned Express Scripts engaged in horizontal price fixing — an illegal agreement between competing companies to manipulate prices — shrinking revenue for the state’s pharmacies and threatening medication access for its patients.

OTHER HEADLINES

 
 

Key Upcoming Dates

 
  • 9/16: Parkinson's Disease — Evidence Report
  • 10/1: Hypertension — Evidence Report
  • 10/15: Friedrich's Ataxia — Draft Evidence Report

Learn more about ICER’s ongoing and recently completed reports:

Email info@icer.org for more information.

When you make a gift to ICER, you help keep ICER independent.  

 
 
 
 
 
LinkedIn Share This Email